Events
NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation – Excerpt from the Press Release: SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR)…
Read More
Meet with Christopher Kata, Director of Sales & Marketing December 3rd – 4th, 2024 at the Clinical Outsourcing Group CRO Summit Raleigh, NC! If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth at your convenience! We’re looking forward to providing live, personalized…
Read More
Excerpt from the Press Release: NEEDHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference (IOVC), taking place October 27-30, 2024,…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years Clinical Outsourcing Group Bay Area meeting on October 8th – 9th in booth #13. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #13 at your convenience! We’re looking forward to…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years SCDM meeting on Sept. 29 – Oct. 2, 2024 in booth #100. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #100 at your convenience! We’re looking forward to providing live,…
Read More Christopher Kata and the TrialStat team are exhibiting at this years DPHARM meeting on September 17th through the 18th in booth #21. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #21 at your convenience! We’re looking forward to providing live, personalized…
Read More
Novel cardiotropic capsids transduce more than 90% of cardiomyocytes in non-human primates (NHPs) and detarget the liver and dorsal root ganglia (DRG); show safety and efficacy in a mouse model of cardiac dysfunction Novel BBB-penetrant capsid transduces more than 50% of neurons in NHPs across spinal cord, cortex, and deep-brain regions and detarget the liver…
Read More